NICE Draft Guidance Rejects Lenacapavir for HIV PrEP in England
NICE has opened consultation on draft guidance that does not recommend lenacapavir for HIV PrEP, finding the six-monthly injection is not value for money for the NHS in England. #SyenzaNews #HTA #HIV #PrEP #MarketAccess
Recent Posts
AI in health technology assessment: what stays human
Sep 10
Rewarding Quality, Not Just Price: What the EU Public Procurement Act Means for Medicines
Sep 10
UK Commission Sets Out a Framework for AI Healthcare Regulation
Sep 10
AI in Portuguese Healthcare: What Should Portugal Want It to Do?
Sep 10
Sandoz Bio100 Biosimilars Plan Targets 100 Products by 2040 and Doubles 2025 Sales by 2035
Sep 9Syenza's Top Picks
Medicare GLP-1 Bridge Tops 500,000 Users in Its First Two Months
Sep 7, 2026
Fifth Circuit Upholds Medicare Drug Price Negotiation Program
Aug 28, 2026
South Africa TB Vaccine Registration Plan Awaits Phase 3
Aug 31, 2026
AI Models Near Perfect Scores on German Medical Licensing Exams
Aug 31, 2026
Linking Drug and Diagnostic Policy Pathways to Reach Patients Most Likely to Benefit
Aug 31, 2026
Cipla TQB2102 Licensing Deal Brings Sino Biopharm’s HER2 ADC to India and South Africa
Sep 1, 2026
Latest News
News
Semaglutide Linked to Fewer Asthma Attacks and COPD Exacerbations in UK Records
Real-world UK data presented at ERS 2026 link semaglutide to fewer asthma attacks and COPD exacerbations. The indication stays metabolic, but the signal raises a real question for value and access teams. #SyenzaNews #MarketAccess #GLP1 #Respiratory
News
FDA Grants Accelerated Approval to Camizestrant for ESR1-Mutated Breast Cancer
Camizestrant (Etcamah) gains accelerated FDA approval for ESR1-mutated advanced breast cancer, with median progression-free survival of 16 months versus 9.2 months in SERENA-6. #SyenzaNews #BreastCancer #FDA #Oncology
News
South Africa Initiates 55,123 People on Twice-Yearly Lenacapavir PrEP
South Africa has initiated 55,123 people on twice-yearly lenacapavir PrEP in the programme’s first 94 days. Demand is strongest in Gauteng and KwaZulu-Natal; branded supply, second-dose retention and the 2027 generic tender are the real constraints. #SyenzaNews #HIVPrevention #Lenacapavir #MarketAccess
News
Novartis and The Max Foundation Mark 25 Years of Cancer Access in LMICs
Novartis and The Max Foundation mark 25 years of partnership that has delivered cancer treatment to more than 100,000 patients across 71 LMICs. The next test is whether the model can carry a broader oncology portfolio and transition to country funding.
#SyenzaNews #MarketAccess #GlobalHealth
News
Proteomic aging clocks detect biological age reversal in IPF drug trial
An Insilico Medicine phase 2a trial found six proteomic aging clocks all detected lower biological age in patients treated with rentosertib, an AI-designed drug for idiopathic pulmonary fibrosis. #SyenzaNews #Proteomics #AgingClocks #DrugDiscovery #IPF
News
Novo Nordisk Halts Ziltivekimab Cardiovascular Programme After Futility Review
Novo Nordisk has stopped the two remaining ziltivekimab heart failure trials after a futility review, leaving ARTEMIS as the last anti-inflammatory cardiovascular outcomes bet. #SyenzaNews #MarketAccess #Cardiology #HTA
News
Aspen Exits Lenacapavir Local Manufacturing, Backs Merck’s Monthly Oral PrEP
Aspen Pharmacare has walked away from local lenacapavir manufacturing over the lack of guaranteed volumes, and is instead backing Merck’s once-monthly oral PrEP pill, alimatravir. #SyenzaNews #HIV #PrEP #MarketAccess
News
Aspen Pharmacare Bets on Manufacturing Rebound and Generic Semaglutide
Aspen Pharmacare posted 22% normalised earnings growth and is betting on a manufacturing rebound and a generic semaglutide rollout for FY2027. #SyenzaNews #Pharma #GLP1 #MarketAccess #SouthAfrica
News
Trump’s MFN Drug Pricing Policy Is Cutting Europe’s Access to New Medicines
Trump’s Most Favored Nation drug pricing policy is already delaying new medicine launches in Europe. Brussels journalist Christoffer Frendesen unpacks the silence, the data, and why it may outlast the Trump presidency. #SyenzaNews #MarketAccess #DrugPricing
News
Medicare GLP-1 Bridge Tops 500,000 Users in Its First Two Months
US Medicare is paying for obesity GLP-1s for the first time, and more than 500,000 seniors signed up in the first two months. Our latest breaks down the $245 price, the $50 copay, and what it means for Lilly and Novo Nordisk. #SyenzaNews #MarketAccess #GLP1 #Medicare
Join Our Newsletter
Get the latest healthcare tech news delivered straight to your inbox.
